The premise, IIUC, is that obesity is driven partly by mucosal overgrowth on the duodenum. This thicker-than-expected layer of mucus is less porous, which leads your digestive system to underestimate the number of calories you've consumed. Revita basically re-surfaces the duodenum.
So, the idea is that you get to a lower weight with the GLP-1 drugs, and then Revita can hopefully reset your set point there.
Their first clinical trial is still in progress, but I think it's interesting to watch.